The Technical Analyst
GlobeStar Therapeutics [GSTC]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
GlobeStar Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
12.50% $0.0009
America/New_York / 3 mai 2024 @ 13:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.047 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Mar 11, 2024 |
| SharesOutstanding: | 1 162.92 mill |
| Avg Daily Volume: | 7.39 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Neutral | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | n/a | n/a | ||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0004 (-148.31%) $-0.0013 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0009 - 0.0009 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-11-23 | Chicoski Robert | Sell | 0 | COMMON STOCK |
| 2021-02-10 | Chicoski Robert | Sell | 0 | COMMON STOCK |
| 2023-02-24 | Katzaroff James C | Buy | 35 000 000 | Options |
| 2021-05-12 | Katzaroff James C | Buy | 30 000 000 | Options |
| 2023-04-03 | Katzaroff James C | Buy | 7 042 253 | Common stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 8 transactions |
| Buy: 207 464 788 | Sell: 0 |
Forecast:
14:40 - $0.0010
Live Trading Signals (every 1 min)
Forecast
1: 13:10 - $0.0010
Forecast 2: 14:00 - $0.0010
Forecast 3: 14:40 - $0.0010
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0009 (12.50% ) |
| Volume | 2.03 mill |
| Avg. Vol. | 7.39 mill |
| % of Avg. Vol | 27.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GSTC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GSTC
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. The company was incorporated in 2016 and is based in Richland, Washington.
Latest Press Releases
2024-03-28 08:15:00 - Press Release
Globestar Therapeutics Update On Project Amethyst(tm) And Recent Financials
Richland, wa / accesswire / march 28, 2024 / globestar therapeutics corporation (otc pink:gstc) (gstc), is a clinical stage pharmaceutical company focused on advancing new therapies for multiple sclerosis (ms) and other neurological diseases, including but not limited to rheumatoid arthritis (ra), released on march 11, 2024 its fiscal year first quarter financials for the quarter ended 12/31/2023. the company reported that $42,800 of cash was used in operating activities vs.
2023-11-02 08:22:00 - Press Release
Globestar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies And Strategies For Multiple Sclerosis Treatment
Richland, wa / accesswire / november 2, 2023 / globestar therapeutics corporation (otc pink:gstc), (gstc), a clinical-stage pharmaceutical company focused on advancing new therapies for multiple sclerosis (ms) and other neurological diseases today announced that building on its recent agreement with smi healthcare llc (smihc) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in india, southeast asia, africa, and the middle east. globestar has also entered into a definitive agreement with advanced innovative partners (aip) for aip to provide advice to globestar and smihc on the global design, strategy and execution of clinical trials, regulatory filings, intellectual property rights filings, and manufacturing for project amethyst™.
2023-09-28 06:22:00 - Press Release
Globestar Therapeutics Enters Into Definitive Agreement With Smi Healthcare To Manage Clinical Trial, Regulatory Filings, Manufacturing And Sales In Mea Region For Multiple Sclerosis Treatment
Richland, wa / accesswire / september 28, 2023 / globestar therapeutics corporation (otc pink:gstc) (gstc), a clinical-stage pharmaceutical company focused on advancing new therapies for multiple sclerosis (ms) and other neurological diseases today announced that it has entered into a definitive agreement with smi healthcare llc (smihc) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in india, southeast asia, africa, and the middle east, excluding israel and iraq, and for government and private aid organizations, for globestar's patented multiple sclerosis treatment. gstc is the exclusive worldwide licensee for project amethyst™, including all patents and patent applications relating thereto, including u...
2021-10-11 08:30:00 - Press Release
Globestar Therapeutics Corporation Has Been Upgraded To The Qb Tier On Otc Markets
Company will move from the pink tier to qb tier effective immediately while retaining the same ticker symbol. richland, wa / accesswire / october 11, 2021 / globestar therapeutics corporation (otcqb:gstc) ( www.globestarthera.com ) headquartered in richland, washington, is a fast-growing company focused on providing medical research, development, and treatments for disease.
2021-10-04 09:00:00 - Press Release
Globestar Therapeutics Corporation Additional Progress Toward A U.s.-based Clinical Trial.
Company has made progress with a major medical center in the northeast and identified a path forward for this pharmaceutical. richland, wa / accesswire / october 4, 2021 / globestar therapeutics corporation (otc pink:gstc) ( www.globestarthera.com ), headquartered in richland, washington, is a fast-growing company focused on providing medical research, development, and treatments for disease.
Latest News
2021-10-11 08:30:00 - Accesswire
GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets
Company will move from the Pink tier to QB tier effective immediately while retaining the same ticker symbol. RICHLAND, WA / ACCESSWIRE / October 11, 2021 / GlobeStar Therapeutics Corporation (OTCQB:GSTC) ( www.globestarthera.com ) headquartered in Richland, Washington, is a fast-growing company focused on providing medical research, development, and treatments for disease.
2021-10-04 09:00:00 - Accesswire
GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.
Company has made progress with a major medical center in the Northeast and identified a path forward for this pharmaceutical. RICHLAND, WA / ACCESSWIRE / October 4, 2021 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) ( www.globestarthera.com ), headquartered in Richland, Washington, is a fast-growing company focused on providing medical research, development, and treatments for disease.
2021-09-20 16:05:00 - Accesswire
GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis
Company has made significant progress and identified a path forward for this pharmaceutical. RICHLAND, WA / ACCESSWIRE / September 20, 2021 / GlobeStar Therapeutics Corporation (OTCBB: GSTC) has filed its latest 8K statement and Edgar filing today.
2021-07-21 08:00:00 - Accesswire
GlobeStar Therapeutics Corporation Unveils New Corporate Website and Branding Campaign
New website goes live in tandem with a major branding campaign to be found in USA Today. RICHLAND, WA / ACCESSWIRE / July 21, 2021 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) is launching its new website at www.globestarthera.com over the next 24 hours.
2021-07-15 07:15:00 - Accesswire
GlobeStar Therapeutics Corporation To Be Seen In The Washington Football Team Yearbook All Season
RICHLAND, WA / ACCESSWIRE / July 15, 2021 / GlobeStar Therapeutics Corporation has partnered with the Washington Football Team Yearbook producers for inclusion in their annual book. GlobeStar Therapeutics Corporation (OTC PINK:GSTC) is partnering with the producers of the Washington Football Team Yearbook for inclusion in their 2021-2022 guide.